Sutro Biopharma, Inc.
STRO
$0.8508
-$0.0518-5.74%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -112.99% | 28.12% | 12.76% | 11.67% | 10.41% |
| Total Depreciation and Amortization | 5.90% | 7.08% | 11.23% | 16.46% | 19.79% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -12.90% | -15.01% | 816.52% | 14.59% | 79.62% |
| Change in Net Operating Assets | 125.89% | -54.90% | -83.23% | -131.19% | -132.92% |
| Cash from Operations | -71.61% | 29.30% | -48.85% | -419.97% | -3,245.00% |
| Capital Expenditure | 28.20% | 44.38% | 55.33% | 47.30% | 45.09% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 56,576.73% | 1,020.83% | -719.68% | -151.55% | 101.44% |
| Cash from Investing | 5,668.50% | 687.69% | -969.48% | -1,214.65% | 88.80% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 67.34% | 42.34% | 17.34% | -7.66% | -33.33% |
| Issuance of Common Stock | 588.10% | 232.34% | 59.53% | -95.63% | -75.35% |
| Repurchase of Common Stock | -3.88% | 1.02% | 12.43% | 19.02% | -5.83% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.00% | -102.53% | 619,027.27% | -- |
| Cash from Financing | -31.62% | -40.51% | -55.33% | 122.63% | 184.71% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 449.75% | 720.48% | -192.53% | -91.87% | 30.72% |